Online Courses

During this recorded 2022 ASCP Annual Meeting session, multidisciplinary faculty discuss the science and latest evidence on emerging biomarkers, resistance mutations, immuno-oncology (I-O) resistance mechanisms, and I-O treatment options (e.g., combination therapy involving CTLA-4 inhibitors) in metastatic NSCLC. Participants will learn how to integrate next generation sequencing (NGS) into their biomarker testing workflows and optimize its use for patients. Finally, faculty share best practices in biomarker testing, reporting, and communication to help pathologists and laboratory professionals guide medical oncologists and other team members in the appropriate diagnosis, testing, and treatment for patients.

Credits

This activity offers 1.0 CME/CMLE credit.

This CME/CMLE-accredited 1-hour molecular tumor board simulation is designed to help pathologists, laboratory professionals, and other members of the interdisciplinary cancer care team gain deeper scientific knowledge and skills in diagnosing, testing, and managing advanced non-small cell lung cancer (NSCLC). Throughout the highly interactive molecular tumor board simulation, a multidisciplinary faculty panel will discuss multiple patient cases involving advanced NSCLC, and you will answer questions designed to help you carefully consider the nuances of each case, building your knowledge and skills related to the detection and optimal management of advanced NSCLC.